Sygnature Discovery

Dr Simon Hirst, CEO and Founder of Sygnature Discovery has been awarded a prestigious honorary degree of Doctor of Science (D.Sc.) by The University of Nottingham. An honorary degree is one of the highest honours that a university can bestow and is reserved for those whose achievements are of such distinction that they provide inspiration to graduates. The ceremony took place on Wednesday 30th July 2025, recognising Simon’s outstanding contribution to science and the pharmaceutical industry. 👏 Join us in celebrating this well-earned recognition – and discover the story behind Simon’s remarkable impact on the pharmaceutical industry and local innovation. 🔗 Read more: https://lnkd.in/eJ2BdsKt #Chemistry #Biotechnology #DrugDiscovery #WeAreUoN

🚀 Accelerating oncology breakthroughs takes more than #innovation, it takes #collaboration. As a proud Dotmatics partner, we empower our customers to transform raw data into deep insight, unlocking the full potential of their research. We’re also thrilled to see Dr. Allan Jordan, our VP of #Oncology Drug Discovery, take part in this fireside conversation hosted by Dotmatics. He’ll explore how #AI, data, and strategic collaboration are reshaping oncology R&D. From #KRAS targeting to AI-driven trial design, discover how today’s tools are helping bring tomorrow’s therapies to patients, faster and smarter. 📅 Don’t miss this virtual session that goes beyond buzzwords and into real-world impact 👇 🔗 https://lnkd.in/emrS75qZ #DrugDiscovery #CancerResearch #Pharma #Biotech #DataAnalytics #SygnatureScience

🎤 Exciting week ahead for Louise Birch, Deputy Director – Computational Chemistry, as she heads to #GRC 2025 in New Hampshire!   Louise will be presenting the story behind Dencatistat, a CTPS1-selective inhibitor discovered through Sygnature’s close collaboration with Step Pharma, a promising new direction in precision #oncology.    Catch her talk: 🗓 Monday 4th August | ⏰ 9:45–10:15 AM 📍 New Frontiers in Oncology Therapies session, Gordon Research Conference, Colby-Sawyer College, New Hampshire, US Title: “Identification of Dencatistat: An Isoform Selective CTPS1 Inhibitor for Multiple Oncology Indications”   We’re proud to see Louise representing the science and spirit of Sygnature on such a prestigious stage.   #GRC2025 #DrugDiscovery #CTPS1 #SmallMolecules Gordon Research Conferences

[PRESS RELEASE] Sygnature Discovery today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. Read all about it in our latest press release below 👇 : https://lnkd.in/dAnsmnry #Chemistry #Biotechnology #Pharma #DrugDiscovery

Since Paul Ehrlich’s original ‘magic bullet’ concepts, antibody-drug conjugates (ADCs) have undergone significant evolution over the years, yet it is only in the last 2 decades that we have seen them adopted as a therapeutic option. From early iterations to modern versions, the ADC field has strived to improve therapeutic windows and patient standard with good yet debatable outcome, targeting mechanisms, and payload efficacy. Click through to our blog by Allan Jordan and Joshua Greally to explore the transformative changes in ADC development on the horizon 🛣: 🟢Combination Therapy ADCs: Dual Payload Strategies 🟢 Expanding ADC Applications beyond Oncology Learn more: https://lnkd.in/dfMrG2kc #Antibody #ADCs #Biotechnology

Antibody-Drug Conjugates (ADCs) still face significant challenges related to patient tolerability and therapeutic window, and ADCs often fail to significantly reduce toxicity compared to traditional cytotoxic agents, highlighting the ongoing struggle to improve specificity and safety. Click through to our blog by Allan Jordan and Joshua Greally to explore the role of selectivity in ADC development 🛣: 🟢 Selective Targeting and Payload Design (‘Selectivity Squared’)  🟢 Multidisciplinary Approach to ADC Development  🟢 Balancing Efficacy and Toxicity to Maximise ADC Therapeutic Index Learn more : https://lnkd.in/d_9rCPXA #Antibody #ADCs #Biotechnology

We're proud to be an official Dotmatics partner, empowering our customers to transform raw data into deep insight by harnessing the true potential of their data.   Take a look at this case study from Dotmatics which highlights Sygnature’s comprehensive expertise with the platform. 🤝   #drugdiscovery #pharma #biotech #dataanalytics

🎉 We’re incredibly proud to share that three of our outstanding Finance colleagues were recognised at this year’s East Midlands Finance Awards, a prestigious event organised by Distinct | B Corp which honours exceptional talent across the region. Tanisha Howell and Joseph Smith were both named finalists in the Rising Star category. An award that celebrates individuals who go above and beyond, demonstrating exceptional promise in their finance careers. 🌟   …. We’re thrilled to announce that Tanisha was crowned the winner! 🏆 victoria smith was also named a finalist in the Unsung Hero category - a fitting tribute to her consistent dedication and behind-the-scenes contributions that keep everything running smoothly. 👏 These nominations and achievements are a proud moment for all of us and a fantastic example of how our company values come to life: collaboration and a shared commitment to excellence. #EMFA2025 #RisingStar #Recognition #Finance #SygnatureDiscovery 

Our ASMS lead Rupert Satchell extols the virtues of this technique in uncovering novel allosteric sites, providing opportunity for structure-based design of allosteric modulators and targeted protein degraders. Read the full case study here 👉 https://lnkd.in/ddbjRNFH #drugdiscovery #pharma #biotechnology

Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy, but discussions often focus on the antibody and the cytotoxic payload, leaving linker technology as an overlooked component. In reality, linker technology is a pivotal aspect that significantly influences ADC efficacy, selectivity and stability. In this blog we take a closer look at why linkers matter and how they contribute to the overall performance of ADCs. Read through the blog below by Allan Jordan and Joshua Greally to explore the role of linker technologies in ADC development 🛣: 🟢 The Importance of Linker Characteristics 🟢 Conjugation Strategies and Their Impact 🟢 The Future of Linker Technology in ADCs #Antibody #ADCs #Biotechnology